Full Press Release Details
Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis.
SGMT
Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis
Key Takeaway: Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease